Multivisceral resection of primary multifocal retroperitoneal sarcomas: a retrospective study from a high-volume sarcoma center
Background: Although surgery plays a vital role in the treatment of primary retroperitoneal sarcoma (RPS), there remain few reports on primary multifocal RPS.
Aim: This study aimed to identify the prognostic factors for primary multifocal RPS in an effort to optimize the clinical management of this malignancy.
Methods: A retrospective analysis was conducted on a cohort of 319 primary RPS patients who underwent radical resection from 2009 to 2021, with postoperative recurrence as the primary endpoint of this study. COX regression was performed to identify the risk factors for postoperative recurrence, and a comparison was made to baseline and prognostic differences between multivisceral resection (MVR) and non-MVR groups with multifocal disease.
Results: There were 31 (9.7%) patients with multifocal disease, the mean tumor burden placed on them was 24.1 ± 11.9 cm, and nearly half of the patients (48.4%) had MVR. Dedifferentiated liposarcoma, well-differentiated liposarcoma, and leiomyosarcoma accounted for 38.7%, 32.3%, and 16.1%, respectively. The 5-year recurrence-free survival rate reached 31.2% (95% CI, 11.2-51.2%) in the multifocal group and 51.8% (95% CI, 44.2-59.4%) in the unifocal group (p = 0.010). Age (HR = 0.916; p = 0.039) and complete resection (HR = 1.861; p = 0.043) were identified as the independent risk factors for the postoperative recurrence of multifocal primary RPS.
Conclusions: Regarding primary multifocal RPS, the overall treatment strategy can be adopted for the treatment of primary RPS, and MVR remains effective in boosting the chance of disease control for a selected group of patients.
Relevance for patients: This study is relevant to patients as it highlights the importance of receiving appropriate treatment for primary RPS, especially for those with multifocal disease. The treatment options should be evaluated carefully to ensure that the patients receive the most effective treatment for their specific type and stage of RPS. The potential risk factors for postoperative recurrence should be well understood to minimize those risks. Ultimately, this study underscores the importance of ongoing research to optimize the clinical management of RPS and improve outcomes for patients
[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7-33.
[2] Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Desa A, Gladdy RA, et al. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Ann Surg Oncol 2021;28:7873-88.
[3] Gronchi A, Lo VS, Fiore M, Mussi C, Stacchiotti S, Collini P, et al. Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients. J Clin Oncol 2009;27:24-30.
[4] Bonvalot S, Rivoire M, Castaing M, Stoeckle E, Le Cesne A, Blay JY, et al. Primary Retroperitoneal Sarcomas: A Multivariate Analysis of Surgical Factors Associated with Local Control. J Clin Oncol 2009;27:31-7.
[5] MacNeill AJ, Gronchi A, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, et al. Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report from the Transatlantic RPS Working Group. Ann Surg 2018;267:959-64.
[6] Fiore M, Brunelli C, Miceli R, Manara M, Lenna S, Rampello NN, et al. A Prospective Observational Study of Multivisceral Resection for Retroperitoneal Sarcoma: Clinical and Patient-Reported Outcomes 1 Year After Surgery. Ann Surg Oncol 2021;28:3904-16.
[7] Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients from the Multiinstitutional Collaborative RPS Working Group. Ann Surg 2016;263:1002-9.
[8] Anaya DA, Lahat G, Liu J, Xing Y, Cormier JN, Pisters PW, et al. Multifocality in Retroperitoneal Sarcoma: A Prognostic Factor Critical to Surgical Decision-Making. Ann Surg 2009;249:137-42.
[9] Toulmonde M, Bonvalot S, Méeus P, Stoeckle E, Riou O, Isambert N, et al. Retroperitoneal Sarcomas: Patterns of Care at Diagnosis, Prognostic Factors and Focus on Main Histological Subtypes: A Multicenter Analysis of the French Sarcoma Group. Ann Oncol 2014;25:735-42.
[10] Tseng WW, Madewell JE, Wei W, Somaiah N, Lazar AJ, Ghadimi MP, et al. Locoregional Disease Patterns in Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcoma: Implications for the Extent of Resection? Ann Surg Oncol 2014;21:2136-43.
[11] Anaya DA, Lahat G, Wang X, Xiao L, Pisters PW, Cormier JN, et al. Postoperative Nomogram for Survival of Patients with Retroperitoneal Sarcoma Treated with Curative Intent. Ann Oncol 2010;21:397-402.
[12] Xue G, Wang Z, Li C, Lv A, Tian X, Wu J, et al. A Novel Nomogram for Predicting Local Recurrence-Free Survival After Surgical Resection for Retroperitoneal Liposarcoma from a Chinese Tertiary Cancer Center. Int J Clin Oncol 2021;26:145-53.
[13] Voros D, Theodorou D, Ventouri K, Prachalias A, Danias N, Gouliamos A. Retroperitoneal Tumors: Do the Satellite Tumors Mean Something? J Surg Oncol 1998;68:30-3.
[14] Tseng WW, Madewell JE, Wei W, Somaiah N, Lazar AJ, Ghadimi MP, et al. Locoregional disease patterns in well differentiated and differentially associated roperitoneal liposarcoma: Implications for the extension of restoration? Ann Surg Oncol. 2014; 21 (7): 2136-2143
[15] Bonvalot S, Raut CP, Pollock RE, Rutkowski P, Strauss DC, Hayes AJ, et al. Technical Considerations in Surgery for Retroperitoneal Sarcomas: Position Paper from E-Surge, a Master Class in Sarcoma Surgery, and EORTC-STBSG. Ann Surg Oncol 2012;19:2981-91.
[16] Fairweather M, Gonzalez RJ, Strauss D, Raut CP. Current Principles of Surgery for Retroperitoneal Sarcomas. J Surg Oncol 2018;117:33-41.
[17] Callegaro D, Fiore M, Gronchi A. Personalizing Surgical Margins in Retroperitoneal Sarcomas. Expert Rev Anticancer Ther 2015;15:553-67.
[18] Salerno KE, Baldini EH. Role of Radiation Therapy in Retroperitoneal Sarcoma. J Natl Compr Canc Netw 2022;20:845-9.
[19] Bonvalot S, Gronchi A, Le Pechoux C, Swallow CJ, Strauss D, Meeus P, et al. Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients with Primary Retroperitoneal Sarcoma (EORTC-62092: STRASS): A Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet Oncol 2020;21:1366-77.
[20] Salerno KE, Alektiar KM, Baldini EH, Bedi M, Bishop AJ, Bradfield L, et al. Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol 2021;11:339-51.
[21] Ma SJ, Oladeru OT, Farrugia MK, Shekher R, Iovoli AJ, Singh AK. Evaluation of Preoperative Chemotherapy or Radiation and Overall Survival in Patients with Nonmetastatic, Resectable Retroperitoneal Sarcoma. JAMA Netw Open 2020;3:e2025529.
[22] Miura JT, Charlson J, Gamblin TC, Eastwood D, Banerjee A, Johnston FM, et al. Impact of Chemotherapy on Survival in Surgically Resected Retroperitoneal Sarcoma. Eur J Surg Oncol 2015;41:1386-92.
[23] Ferrari A, Sultan I, Huang TT, Rodriguez-Galindo C, Shehadeh A, Meazza C, et al. Soft Tissue Sarcoma Across the Age Spectrum: A Population-Based Study from the Surveillance Epidemiology and End Results Database. Pediatr Blood Cancer 2011;57:943-9.
[24] Smith HG, Thomas JM, Smith MJ, Hayes AJ, Strauss DC. Multivisceral Resection of Retroperitoneal Sarcomas in the Elderly. Eur J Cancer 2016;69:119-26.
[25] Sourrouille I, Macovei R, Faron M, Le Péchoux C, Mir O, Adam J, et al. Long-Term Outcome After Surgery for a Localized Retroperitoneal Soft Tissue Sarcoma in Elderly Patients: Results from a Retrospective, SingleCenter Study. Ann Surg Oncol 2018;25:2201-8.
[26] Zhuang A, Lu W, Fang Y, Ma L, Xu J, Wang J, et al. Prognostic Factors and Nomogram Construction for First Local Recurrent Retroperitoneal Sarcoma Following Surgical Resection: A Single Asian Cohort of 169 Cases. Front Oncol 2022;12:856754.